Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL

Key Points • Similar mutation frequency, type, and location in TP53 between 849 patients newly diagnosed with CLL and 381 patients with HCMBL.• Having multiple TP53 abnormalities increased the risk of progression to therapy and shortened the overall survival.

[1]  R. Foà,et al.  P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE , 2022, HemaSphere.

[2]  F. Bosch,et al.  Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony , 2021, Blood.

[3]  D. Rossi,et al.  TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia , 2021, Clinical Cancer Research.

[4]  A. Wiestner,et al.  Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib , 2021, Clinical Cancer Research.

[5]  Š. Pospíšilová,et al.  Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options , 2021, Blood.

[6]  T. Shanafelt,et al.  The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL , 2021, Blood.

[7]  A. Neri,et al.  Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients , 2020, Scientific Reports.

[8]  J. Cerhan,et al.  Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond the CLL international prognostic index , 2020, American journal of hematology.

[9]  T. Stankovic,et al.  Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial , 2020, Leukemia.

[10]  H. Döhner,et al.  Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). , 2019, Haematologica.

[11]  J. Pagel,et al.  Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry , 2019, Clinical lymphoma, myeloma & leukemia.

[12]  P. Abrisqueta,et al.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. , 2019, Blood.

[13]  Savvas Kinalis,et al.  Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment , 2018, Haematologica.

[14]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[15]  K. Stamatopoulos,et al.  ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation , 2018, Leukemia.

[16]  D. Rossi,et al.  The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. , 2017, Hematology. American Society of Hematology. Education Program.

[17]  A. López-Guillermo,et al.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.

[18]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[19]  A. Valencia,et al.  Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.

[20]  Jared Evans,et al.  PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data , 2014, Bioinform..

[21]  Raul Rabadan,et al.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.

[22]  M. Cazzola,et al.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.

[23]  H. Döhner,et al.  Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Morgan,et al.  Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Döhner,et al.  TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[27]  Š. Pospíšilová,et al.  Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.

[28]  D. Rossi,et al.  The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors , 2009, British journal of haematology.

[29]  D. Rossi,et al.  The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.

[30]  Susan O'Brien,et al.  De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. , 2008, Blood.

[31]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[32]  Paolo Ghia,et al.  Diagnostic criteria for monoclonal B‐cell lymphocytosis , 2005, British journal of haematology.

[33]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[34]  T. Haferlach,et al.  The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.